Following a reverse merger with TuHURA Biosciences in October 2024, the company transformed into TuHURA Biosciences, Inc., trading under the new ticker symbol HURA on the Nasdaq Capital Market. TuHURA is a Phase 3 immuno-oncology company developing therapeutics intended to overcome resistance to cancer immunotherapy, with focus on the VISTA-inhibiting antibody TBS-2025 in blood-related cancers.
Cyborg Score Rationale
In 2025, market capitalization decreased 73.43% from January to December, declining from $172.95M to $45.95M. Over the past 12 months, the stock has lost 94.2%. The company faces significant financial and operational challenges following its transformation.
Top Insights
(October 2024) Completed merger with TuHURA Biosciences, rebranding to TuHURA Biosciences, Inc. with new ticker HURA
(October 2024) Implemented 1-for-35 reverse stock split in connection with TuHURA merger
(March 2026) CMO appointment to lead development of VISTA-blocking antibody TBS-2025 in blood cancers
Primary focus shifted to immuno-oncology and overcoming cancer immunotherapy resistance following merger
Named Competitors
Oncology Pipeline — Oncology and neuroscience therapeutics
Moderna Therapeutics — mRNA-based therapeutic platforms
Cell Therapy Platform — Cell engineering and immunotherapy
Recent Developments
(March 2026) Dr. Craig L. Tendler appointed to lead VISTA-blocking antibody TBS-2025 development strategy
(October 2024) Merger with TuHURA Biosciences completed; company renamed to TuHURA Biosciences, Inc.
(April 2024) PIPE investment transaction with TuHURA Biosciences announced
Open the full interactive Kintara Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.